O	0	5	Phase
O	6	9	III
O	10	14	open
O	14	15	-
O	15	20	label
O	21	31	randomized
O	32	37	study
O	38	40	of
B-intervention	41	49	eribulin
I-intervention	50	58	mesylate
O	59	65	versus
B-control	66	78	capecitabine
O	79	81	in
O	82	90	patients
O	91	95	with
O	96	103	locally
O	104	112	advanced
O	113	115	or
O	116	126	metastatic
O	127	133	breast
O	134	140	cancer
O	141	151	previously
O	152	159	treated
O	160	164	with
O	165	167	an
O	168	181	anthracycline
O	182	185	and
O	186	187	a
O	188	194	taxane
O	194	195	.

O	196	200	This
O	201	206	phase
O	207	210	III
O	211	221	randomized
O	222	227	trial
O	228	229	(
O	229	243	ClinicalTrials
O	243	244	.
O	245	248	gov
O	249	259	identifier
O	259	260	:
O	261	272	NCT00337103
O	272	273	)
O	274	282	compared
O	283	291	eribulin
O	292	296	with
O	297	309	capecitabine
O	310	312	in
O	313	321	patients
O	322	326	with
O	327	334	locally
O	335	343	advanced
O	344	346	or
O	347	357	metastatic
O	358	364	breast
O	365	371	cancer
O	372	373	(
O	373	376	MBC
O	376	377	)
O	377	378	.

B-eligibility	379	384	Women
I-eligibility	385	389	with
I-eligibility	390	393	MBC
I-eligibility	394	397	who
I-eligibility	398	401	had
I-eligibility	402	410	received
I-eligibility	411	416	prior
I-eligibility	417	430	anthracycline
I-eligibility	430	431	-
I-eligibility	432	435	and
I-eligibility	436	442	taxane
I-eligibility	442	443	-
I-eligibility	443	448	based
I-eligibility	449	456	therapy
O	457	461	were
O	462	470	randomly
O	471	479	assigned
O	480	482	to
O	483	490	receive
O	491	499	eribulin
O	500	502	or
O	503	515	capecitabine
O	516	518	as
O	519	524	their
O	525	530	first
O	530	531	-
O	531	532	,
O	533	539	second
O	539	540	-
O	540	541	,
O	542	544	or
O	545	550	third
O	550	551	-
O	551	555	line
O	556	568	chemotherapy
O	569	572	for
O	573	581	advanced
O	581	582	/
O	582	592	metastatic
O	593	600	disease
O	600	601	.

O	602	616	Stratification
O	617	624	factors
O	625	629	were
O	630	635	human
O	636	645	epidermal
O	646	652	growth
O	653	659	factor
O	660	668	receptor
O	668	669	-
O	669	670	2
O	671	672	(
O	672	676	HER2
O	676	677	)
O	678	684	status
O	685	688	and
O	689	699	geographic
O	700	706	region
O	706	707	.

O	708	717	Coprimary
O	718	721	end
O	722	728	points
O	729	733	were
B-outcome-Measure	734	741	overall
I-outcome-Measure	742	750	survival
I-outcome-Measure	751	752	(
I-outcome-Measure	752	754	OS
I-outcome-Measure	754	755	)
O	756	759	and
B-outcome-Measure	760	771	progression
I-outcome-Measure	771	772	-
I-outcome-Measure	772	776	free
I-outcome-Measure	777	785	survival
I-outcome-Measure	786	787	(
I-outcome-Measure	787	790	PFS
I-outcome-Measure	790	791	)
O	791	792	.

B-outcome	793	799	Median
I-outcome	800	802	OS
I-outcome	803	808	times
O	809	812	for
O	813	821	eribulin
O	822	823	(
O	823	824	n
O	825	826	=
B-intervention-participants	827	830	554
O	830	831	)
O	832	835	and
O	836	848	capecitabine
O	849	850	(
O	850	851	n
O	852	853	=
B-control-participants	854	857	548
O	857	858	)
O	859	863	were
B-iv-cont-median	864	866	15
I-iv-cont-median	866	867	.
I-iv-cont-median	867	868	9
O	869	872	and
B-cv-cont-median	873	875	14
I-cv-cont-median	875	876	.
I-cv-cont-median	876	877	5
I-cv-cont-median	878	884	months
O	884	885	,
O	886	898	respectively
O	899	900	(
O	900	906	hazard
O	907	912	ratio
O	913	914	[
O	914	916	HR
O	916	917	]
O	917	918	,
O	919	920	0
O	920	921	.
O	921	923	88
O	923	924	;
O	925	927	95
O	927	928	%
O	929	931	CI
O	931	932	,
O	933	934	0
O	934	935	.
O	935	937	77
O	938	940	to
O	941	942	1
O	942	943	.
O	943	945	00
O	945	946	;
O	947	948	P
O	949	950	=
O	951	952	.
O	952	955	056
O	955	956	)
O	956	957	.

B-outcome	958	964	Median
I-outcome	965	968	PFS
I-outcome	969	974	times
O	975	978	for
O	979	987	eribulin
O	988	991	and
O	992	1004	capecitabine
O	1005	1009	were
B-iv-cont-median	1010	1011	4
I-iv-cont-median	1011	1012	.
I-iv-cont-median	1012	1013	1
O	1014	1017	and
B-cv-cont-median	1018	1019	4
I-cv-cont-median	1019	1020	.
I-cv-cont-median	1020	1021	2
I-cv-cont-median	1022	1028	months
O	1028	1029	,
O	1030	1042	respectively
O	1043	1044	(
O	1044	1046	HR
O	1046	1047	,
O	1048	1049	1
O	1049	1050	.
O	1050	1052	08
O	1052	1053	;
O	1054	1056	95
O	1056	1057	%
O	1058	1060	CI
O	1060	1061	,
O	1062	1063	0
O	1063	1064	.
O	1064	1066	93
O	1067	1069	to
O	1070	1071	1
O	1071	1072	.
O	1072	1074	25
O	1074	1075	;
O	1076	1077	P
O	1078	1079	=
O	1080	1081	.
O	1081	1083	30
O	1083	1084	)
O	1084	1085	.

B-outcome	1086	1095	Objective
I-outcome	1096	1104	response
I-outcome	1105	1110	rates
O	1111	1115	were
B-iv-bin-percent	1116	1118	11
I-iv-bin-percent	1118	1119	.
I-iv-bin-percent	1119	1120	0
I-iv-bin-percent	1120	1121	%
O	1122	1125	for
O	1126	1134	eribulin
O	1135	1138	and
B-cv-bin-percent	1139	1141	11
I-cv-bin-percent	1141	1142	.
I-cv-bin-percent	1142	1143	5
I-cv-bin-percent	1143	1144	%
O	1145	1148	for
O	1149	1161	capecitabine
O	1161	1162	.

B-outcome	1163	1169	Global
I-outcome	1170	1176	health
I-outcome	1177	1183	status
O	1184	1187	and
B-outcome	1188	1195	overall
I-outcome	1196	1203	quality
I-outcome	1203	1204	-
I-outcome	1204	1206	of
I-outcome	1206	1207	-
I-outcome	1207	1211	life
I-outcome	1212	1218	scores
O	1219	1223	over
O	1224	1228	time
O	1229	1233	were
O	1234	1241	similar
O	1242	1244	in
O	1245	1248	the
O	1249	1258	treatment
O	1259	1263	arms
O	1263	1264	.

O	1265	1269	Both
O	1270	1280	treatments
O	1281	1284	had
O	1285	1295	manageable
O	1296	1302	safety
O	1303	1311	profiles
O	1312	1322	consistent
O	1323	1327	with
O	1328	1333	their
O	1334	1339	known
O	1340	1347	adverse
O	1348	1355	effects
O	1355	1356	;
O	1357	1361	most
O	1362	1369	adverse
O	1370	1376	events
O	1377	1381	were
O	1382	1387	grade
O	1388	1389	1
O	1390	1392	or
O	1393	1394	2
O	1394	1395	.

O	1396	1398	In
O	1399	1403	this
O	1404	1409	phase
O	1410	1413	III
O	1414	1419	study
O	1419	1420	,
O	1421	1429	eribulin
O	1430	1433	was
O	1434	1437	not
O	1438	1443	shown
O	1444	1446	to
O	1447	1449	be
O	1450	1458	superior
O	1459	1461	to
O	1462	1474	capecitabine
O	1475	1479	with
O	1480	1486	regard
O	1487	1489	to
O	1490	1492	OS
O	1493	1495	or
O	1496	1499	PFS
O	1499	1500	.
